ArticleInfection and immunity2007
Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2.
Article in Infection and immunity, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 105 citations in OpenAlex.
- Disruption of quorum sensing and biofilm formation by lawsone in gram-negative bacteria.Microbiology spectrum · 2026Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Review
- Serratia sp. traits distinguish the lung microbiome of patients with tuberculosis and non-tuberculous mycobacterial lung diseases.PloS one · 2025Article
- Recombinant serralysin metalloproteases D enhances the intracellular replication of infectious bovine rhinotracheitis virus.Frontiers in microbiology · 2025Article
- Evaluation of Immunostimulatory Effects of Bacterial Lysate Proteins on THP-1 Macrophages: Pro-inflammatory Cytokine Response and Proteomic Profiling.Journal of immunology research · 2025Article
- Exploring the Interplay of Gut Microbiota and Systemic Inflammation in Pediatric Obstructive Sleep Apnea Syndrome and Its Impact on Blood Pressure Status: A Cross-Sectional Study.International journal of molecular sciences · 2024Article
- Management of virulence inRSC advances · 2023Article
- Collateral beauty in the damages: an overview of cosmetics and therapeutic applications of microbial proteases.Archives of microbiology · 2023Review
- Modulating the Microbiome for Crohn's Disease Treatment.Gastroenterology · 2023Review
- IgaA Protein, GumB, Has a Global Impact on the Transcriptome and Surface Proteome of Serratia marcescens.Infection and immunity · 2022Article
- Insecticidal Serralysin ofFrontiers in microbiology · 2022Article
- Coumarin Exhibits Broad-Spectrum Antibiofilm and Antiquorum Sensing Activity against Gram-Negative Bacteria:ACS omega · 2021Article
- Biofabrication of Gold Nanoparticles UsingACS omega · 2021Article
- Xylitol Inhibits Growth and Blocks Virulence inMicroorganisms · 2021Article
- Biofabricated silver nanoparticles exhibit broad-spectrum antibiofilm and antiquorum sensing activity against Gram-negative bacteria.RSC advances · 2021Article
- Sotolon is a natural virulence mitigating agent in Serratia marcescens.Archives of microbiology · 2021Article
- Cross-Talk Between Intestinal Microbiota and Host Gene Expression in Gilthead Sea Bream (Frontiers in physiology · 2021Article
- Quorum sensing-regulated functions ofIranian journal of microbiology · 2020Article
- Plasma amino acid profiles in dogs with inflammatory bowel disease.Journal of veterinary internal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Serratia marcescens-derived protease serralysin is considered to play an important role in the pathogenesis of infection. Protease-activated receptor 2 (PAR-2) is activated by trypsin and also several other trypsin-like serine proteases, leading to the modulation of inflammatory and immune responses. However, little is known about the activation of PAR-2 by bacterial proteases and its roles in bacterial infection. In this study, we investigated whether S. marcescens serralysin activates host inflammatory responses through PAR-2. Our results demonstrated that serralysin induces interleukin-6 (IL-6) and IL-8 mRNA expression in a human lung squamous cell carcinoma, EBC-l cells. In addition, serralysin activated activator protein 1 (AP-1)-, CCAAT/enhancer-binding protein (C/EBP)-, and nuclear factor-kappaB (NF-kappaB)-driven promoters in EBC-1 cells. An electrophoretic mobility shift assay showed that serralysin activates the binding of AP-1, C/EBPbeta, and NF-kappaB in the cells. Inactivation of serralysin resulted in the failure of transactivation of AP-1-, C/EBP-, and NF-kappaB-driven promoters in the cells. Furthermore, serralysin activated AP-1-, C/EBP-, and NF-kappaB-driven promoters via PAR-2 in HeLa cells. PAR-2 antagonist peptides decreased serralysin-induced transactivation of AP-1-, C/EBP-, and NF-kappaB-driven promoters in EBC-1 cells. Considered together, these results suggest that serralysin requires PAR-2 to activate the critical transcription factors AP-1, C/EBPbeta, and NF-kappaB for host inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.